The Genitourinary Cancers Steering Committee (GUSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in genitourinary cancers. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The GUSC's membership comprises NCTN group representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Co-Chairs
Jason Efstathiou, M.D., D.Phil.
Massachusetts General Hospital
Daniel W. Lin, M.D.
University of Washington
Michael J. Morris, M.D.
Memorial Sloan Kettering Cancer Center
Members
Melissa L. Abel, M.D.
National Cancer Institute
Rahul Raj Aggarwal, M.D.
University of California, San Francisco
Leonard J. Appleman, M.D., Ph.D.
University of Pittsburgh Medical Center
Leslie Ballas, M.D.
Cedars-Sinai Medical Center
Karla Ballman, Ph.D.
Mayo Clinic
Alejandro Berlin, M.D., M.Sc.
University Health Network, Princess Margaret Cancer Centre
Toni K. Choueiri, M.D.
Dana-Farber Cancer Institute
Anthony Crispino
UsTOO Las Vegas
Elie G. Dib, M.D., M.S., FACP
Trinity Health - IHA Medical Group
Jared Foster, Ph.D.
National Cancer Institute
Matthew D. Galsky, M.D.
Icahn School of Medicine at Mount Sinai
Petros Grivas, M.D., Ph.D., FASCO
Fred Hutchinson Cancer Center
Naomi B. Haas, M.D.
University of Pennsylvania
Sebastien J. Hotte, M.D., M.Sc., FRCPC
Juravinsky Cancer Centre
Wassim Kassouf, M.D.
McGill University
Seth P. Lerner, M.D.
Baylor College of Medicine
Bhupinder S. Mann, M.B.B.S.
National Cancer Institute
David T. Marshall, M.D., M.S.
Medical University of South Carolina
Joshua J. Meeks, M.D., Ph.D.
Northwestern University
Margaret M. Mooney, M.D., M.B.A.
National Cancer Institute
Paul L. Nguyen, M.D.
Dana Farber Cancer Institute
Daniel P. Petrylak, M.D.
Yale University
Susan C. Poteat, M.S.
KidneyCAN
Jonathan R. Rosenberg, M.D.
Memorial Sloan Kettering Cancer Center
Matthew Schipper, Ph.D., M.S.
University of Michigan
Daniel E. Spratt, M.D., Ph.D.
University Hospitals, Cleveland Medical Center
Catherine M. Tangen, Dr.P.H.
Fred Hutchinson Cancer Center
Victoria Wang, Ph.D.
Dana Farber Cancer Institute
NCI CCCT Program Director
Abdul Tawab Amiri, Ph.D.
atawab@mail.nih.gov